<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">EPLERENONE</span><br/>(e-ple're-none)<br/><span class="topboxtradename">Inspra<br/></span><b>Classifications:</b> <span class="classification">electrolye &amp; water balance agent</span>; <span class="classification">selective aldosterone receptor antagonist</span><br/><b>Prototype: </b>Spironolactone<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg, 50 mg, 100 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Binds to mineralocorticoid receptors and blocks the binding of aldosterone, a component of the renin-angiotensin-aldosterone-system
         (RAAS). Thus eplerenone blocks the primary effect of aldosterone which is sodium reabsorption.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Lowers blood pressure by inhibiting sodium and water retention thus reducing total plasma volume.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of hypertension, alone or with other antihypertensive agents. Adjunctive therapy for post MI heart failure.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Serum potassium &gt;5.5 meq/L; type 2 diabetes with microalbuminuria; serum creatinine &gt;2.0 mg/dL in males or &gt;1.8 mg/dL in females;
         creatinine clearance 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic impairment; concomitant use of another mineralocorticoid receptor blocker and ACE inhibitors or angiotensin II antagonists;
         concomitant treatment with moderate inhibitors of CYP450 3A4 (e.g., fluconazole, erythromycin, verapamil, saquinavir); pregnancy
         (category B); lactation; safety and efficacy in pediatric patients are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 50 mg once daily, may be increased to 50 mg b.i.d. or 100 mg q.d., if inadequate response after 4 wk<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not administer in combination with potassium supplements or potassium-sparing diuretics.</li>
<li>Manufacturer recommends dosage reduction to 25 mg once daily with concurrent administration of erythromycin, saquinavir, verapamil,
            or fluconazole.
         </li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Fatigue, flu-like syndrome. <span class="typehead">CNS:</span> Headache, dizziness. <span class="typehead"> CV:</span> Angina, <span class="speceff-life">MI</span>. <span class="typehead"> GI:</span>  Diarrhea, abdominal pain. <span class="typehead">Endocrine:</span> Gynecomastia. <span class="typehead">Metabolic:</span>
<span class="speceff-common">Hyperkalemia</span>, increased GGT, hypercholesterolemia, hypertriglyceridemia, decreased sodium levels. <span class="typehead">Respiratory:</span> Cough. <span class="typehead">Urogenital:</span> Albuminuria, abnormal vaginal bleeding. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">ace inhibitors</span>, <span class="classification">angiotensin ii receptor blockers</span>, <span class="classification">azole antifungals</span> (e.g., <b>fluconazole,</b>
<b>itraconazole,</b>
<b>ketoconazole</b>)
      				<b>, erythromycin,</b>
<b>saquinavir,</b>
<b>verapamil</b> may increase risk of hyperkalemia. <span class="typehead">Food:</span>
<b>Potassium</b>-containing <span class="classification">salt substitutes</span> may increase risk of hyperkalemia. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed. <span class="typehead"> Peak:</span>  1.5 h. <span class="typehead">Distribution:</span> 50% protein bound, primarily to alpha1-acid glycoproteins. <span class="typehead">Metabolism:</span> Metabolized in liver by CYP3A4. <span class="typehead">Elimination:</span> 32% excreted in feces, 67% excreted in urine. <span class="typehead">Half-Life:</span> 46 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor cardiovascular status with frequent BP determinations. Note that BP lowering usually occurs within 2 wk with maximal
            antihypertensive effects achieved within 4 wk.
         </li>
<li>Lab tests: Monitor baseline and periodic serum potassium, serum sodium, renal function tests, lipid profile, and LFTs. Monitor
            type 2 diabetics for microalbuminuria.
         </li>
<li>Concurrent drugs: Monitor serum potassium levels more frequently when patient also receiving an ACE inhibitor or an angiontensin
            II receptor antagonist. Monitor frequently for lithium toxicity with concurrent use.
         </li>
<li>Withhold drug and notify physician for any of the following: serum potassium &gt;5.5 mEq/L, serum creatinine &gt;2.0 mg/dL in males
            or &gt;1.8 mg/dL in females, creatinine clearance 
      </li></ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not use potassium supplements, salt substitutes containing potassium, or contraindicated drugs (e.g., ketoconazole, itraconazole)
            without consulting physician.
         </li>
<li>Do not use OTC nonsteroidal anti-inflammatory drugs without consulting physician.</li>
<li>Do not breast feed without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>